Somahlution
Marizyme Inc is a medical technology company that develops and markets DuraGraft, the first and only FDA-cleared solution for flushing and storage of saphenous vein grafts during coronary artery bypass grafting (CABG) surgery, serving hospitals and cardiovascular surgery centers.
- Company typePrivate
- Founded2010
- HeadquartersJupiter, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Somahlution does
Marizyme Inc is a privately held medical technology company headquartered at 1645 Palm Beach Lakes Blvd, Suite 1200, West Palm Beach, Florida. The firm develops and commercializes a single product, DuraGraft, which is the first and only FDA-cleared solution indicated for the flushing and storage of saphenous vein grafts during Coronary Artery Bypass Grafting (CABG) surgery. The company serves hospitals and cardiovascular surgery centers performing CABG procedures, where harvested saphenous veins are vulnerable to oxidative damage during the intraoperative period between harvest and implantation. The firm was founded in 2010 and operates with a headcount of 1–10 employees, consistent with a focused single-product specialty medical device company.
DuraGraft is a vascular graft protection solution designed to be applied to saphenous vein grafts ex vivo to reduce oxidative damage during intraoperative storage, maintain endothelial cell viability, and preserve structural integrity of the conduit. Clinical evidence cited by the company indicates that saphenous vein grafts stored in DuraGraft exhibit significantly less wall thickening at 12 months post-CABG compared to grafts stored in saline, the historical standard. The technology operates as a single-use intraoperative consumable used at the point of care by cardiac surgical teams, and is regulated as an FDA-cleared medical device under 21 CFR Part 820 quality regulations.
The revenue model is not publicly disclosed, and the source materials do not specify pricing, distribution channels, or unit volumes. Given the single-product, hospital-channel profile of the business, monetization most likely occurs through unit sales of DuraGraft consumables to cardiovascular surgery departments via standard medical device distribution channels. No information on distributor agreements, GPO contracts, sales force composition, or capital structure is available in the source data, leaving commercial mechanics largely opaque.
Somahlution firmographics
Firmographics- Name
- Somahlution
- Legal name
- Marizyme Inc
- Website
- https://somahlution.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Marizyme Inc is a medical technology company that develops and markets DuraGraft, the first and only FDA-cleared solution for flushing and storage of saphenous vein grafts during coronary artery bypass grafting (CABG) surgery, serving hospitals and cardiovascular surgery centers.
- Ownership category
- akta.pro rank
Somahlution industry classification
Industry- Product category
- Vascular Surgery Medical Devices
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where Somahlution is headquartered
LocationHeadquarters
- HQ city
- Jupiter
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Somahlution business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Somahlution product offering
Product offeringCore offering
Somahlution develops and markets DuraGraft, an FDA-cleared medical technology solution used during Coronary Artery Bypass Grafting (CABG) surgery for the flushing and storage of saphenous vein grafts. The product is designed to reduce oxidative damage during intraoperative storage and to maintain cell viability and structural integrity of the graft prior to transplantation.
Product overview
Marizyme Inc offers a single unified medical technology product: DuraGraft. DuraGraft is an FDA-cleared vascular graft protection solution specifically designed for use during Coronary Artery Bypass Grafting (CABG) surgery. The technology focuses on protecting the structural integrity of harvested saphenous vein grafts during the intraoperative storage period.
Differentiator
Problem solved
Functional benefit
Brands
- DuraGraft: The First and Only FDA-cleared solution for the flushing and storage of saphenous vein grafts during Coronary Artery Bypass Grafting (CABG). Designed to help reduce oxidative damage during intraoperative storage, and to maintain cell viability and structural integrity.
Products and services
- DuraGraft DuraGraft is an FDA-cleared vascular graft protection solution used during Coronary Artery Bypass Grafting (CABG) surgery for the flushing and storage of saphenous vein grafts. It is designed to reduce oxidative damage during intraoperative storage and to maintain cell viability and structural integrity. It is intended for use by cardiac surgery teams in hospitals and cardiovascular surgery centers.
Quantifiable outcome
- Saphenous vein grafts stored in DuraGraft exhibited significantly less wall thickening at 12 months post-CABG compared to those stored in saline.
Companies that use Somahlution
Customer profileSegments1 record
Ideal customer profiles1 record
Somahlution technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Somahlution partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Somahlution competitors and assessment
Company assessmentDirect peers
- Adienne Pharma & Biotech: Specializes in organ, tissue, and cell preservation solutions (e.g., Celsior, Custodiol) used in transplant and cardiac surgery, the same clinical problem space as DuraGraft — protecting harvested biological tissue from ischemic and oxidative damage. Highly comparable mechanism and customer set (cardiac surgery centers).
- Artivion (formerly CryoLife): Develops, manufactures, and commercializes products for cardiac and vascular surgery including tissue preservation, BioGlue surgical adhesive, and On-X mechanical heart valves. Directly comparable as a cardiac-surgery-focused company with tissue/graft protection offerings and overlap in CABG-adjacent customers.
- XVIVO Perfusion: Specialist in organ and tissue preservation, including machine perfusion and storage solutions for transplant and cardiac applications. Closely comparable niche focus on protecting harvested biological tissue — directly analogous technology and clinical use case to DuraGraft.
Broad incumbents
- LivaNova: Major cardiovascular surgery company offering heart-lung machines, oxygenators, and cardioplegia solutions used in CABG. Comparable end customer (cardiac surgery teams, perfusionists) and adjacency through intraoperative solutions used during CABG procedures.
- Getinge (Cardiovascular): Provides cardiovascular surgery equipment, perfusion disposables, and operating-room solutions used in CABG workflows. Comparable through shared perfusion/cabg customer base and OR-channel access, with broad portfolio rather than a single niche product.
- Medtronic: Largest cardiovascular device company with broad CABG and interventional cardiology portfolios. Comparable as a large incumbent serving cardiac surgeons and perfusionists with overlapping workflow touchpoints, though no direct DuraGraft-equivalent product.
- Abbott Cardiovascular: Broad cardiovascular portfolio spanning interventional and surgical heart disease products. Comparable as a scaled incumbent serving cardiac surgery centers, with the channel and resources to enter graft protection if commercially attractive.
- Edwards Lifesciences: Cardiac surgery and structural heart leader with surgical tissue heart valves and critical care monitoring used in CABG. Comparable through shared cardiac surgery customers and operating-room channel, though focused on valves rather than graft protection.
- Baxter International: Surgical solutions business includes products used in operating rooms and cardiac surgery (e.g., infusion systems, surgical sealants). Comparable through overlapping OR and perfusion customers and through incumbency in surgical fluids and adjunctive products.
- Terumo Cardiovascular: Global supplier of cardiovascular surgery products including perfusion systems, oxygenators, and surgical instruments for CABG. Operates in the same surgical workflow and customer base as DuraGraft, with broader portfolio reach into the operating room.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights4 records
Customer concentration
Somahlution social profiles
Digital presenceSomahlution compliance and trust
Trust signalCompliance1 record
Somahlution financial estimates
Financial estimateRevenue estimate
Valuation estimate
Somahlution leadership team
Management profileNumber of profiles
Somahlution funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Somahlution M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Somahlution
What does Somahlution do?
Somahlution develops and markets DuraGraft, an FDA-cleared medical technology solution used during Coronary Artery Bypass Grafting (CABG) surgery for the flushing and storage of saphenous vein grafts. The product is designed to reduce oxidative damage during intraoperative storage and to maintain cell viability and structural integrity of the graft prior to transplantation.
Is Somahlution a public or private company?
Somahlution is a private company. It is classified as unknown and is currently operating.
When was Somahlution founded?
Somahlution was founded in 2010. It employs 1 to 10 people.
Where is Somahlution based?
Somahlution is headquartered in Jupiter, United States, in the North America region.
Who are Somahlution's main competitors?
Direct peers on record are Adienne Pharma & Biotech, Artivion (formerly CryoLife) and XVIVO Perfusion. Broad incumbents are LivaNova, Getinge (Cardiovascular), Medtronic, Abbott Cardiovascular, Edwards Lifesciences, Baxter International and Terumo Cardiovascular.
Does Somahlution have an API?
No public API is recorded for Somahlution.
What industry is Somahlution in?
Somahlution's product category is Vascular Surgery Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its SIC code is 3842.